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Abstract: There are two main mechanisms by which iron overload develops in thalassemias: 
increased  iron  absorption  due  to ineffective  erythropoiesis  and  blood  transfusions. In 
nontransfused patients with severe thalassemia, abnormal dietary iron absorption increases 
body iron  burden  between  2  and  5  g  per  year.  If  regular  transfusions are  required,  this 
doubles  the  rate  of  iron  accumulation  leading  to  earlier  massive  iron  overload  and  iron-
related damage. Iron metabolism largely differs between thalassemias and sickle cell disease, 
but  chronic  transfusion  therapy  partially  normalize  many  of  the  disparities  between  the 
diseases, making iron overload an important issue to be considered in the management of 
patients with sickle cell disease too. The present review summarizes the actual knowledge on 
the regulatory pathways of iron homeostasis. In particular, the data presented indicate the 
inextricably link between erythropoiesis and iron metabolism and the key role of hepcidin in 
coordinating  iron  procurement  according  to  erythropoietic  requirement.  The  role  of 
erythropoietin, hypoxia, erythroid-dependent soluble factors and iron in regulating hepcidin 
transcription are discussed as well as differences and similarities in iron homeostasis between 
thalassemia syndromes and sickle cell disease. 
Introduction: In humans total body iron stores is 
maintained normally within the range of 200-1500 
mg (in men, the normal concentration of iron in the 
storage pool is 13 mg/Kg and in women 5 mg/kg) 
by  adequate  adjustment  of  intestinal  iron 
absorption,  since  no  excretory  mechanisms  exist
1. 
Iron  overload  is  a  common  complication  of 
thalassemia syndromes which could lead per se to 
the  development  of  organ  damage  and  increased 
mortality
2.  There  are  two  main  mechanisms  by 
which  iron  overload  develops  in  thalassemias: 
increased  iron  absorption  due  to  ineffective 
erythropoiesis  and  blood  transfusions.  Due  to  the 
different physiopathology of anemia in thalassemia 
and  sickle  cell  disease  (SCD),  and  the  different 
indications in the use of transfusions in thalassemia 
major,  intermedia,  and  SCD,  there  are  significant 
differences in the physiopathology of iron overload 
and iron-related complications in these disorders. Medit J Hemat Infect Dis 2009; 1; Open Journal System 
Figure 1. Body iron homeostasis.
Iron  metabolism:  Body  iron  pathways. Because 
there  is  no  known  regulated  mechanism  for  iron 
excretion, and the amount of iron entering the body 
each day represents less than 0.1% of the total body 
iron  endowment,  most  circulating  iron  must  be 
derived from the recycling of  iron  already  within 
the system
3 (Figure 1). From a quantitative point of 
view,  the  most  important  pathway  of  iron 
metabolism  is the  unidirectional  recycling of  iron 
from senescent red blood cells to the erythroid bone 
marrow through  macrophages
1,4. Renewed interest 
has  been  developed  on  the  role  of  macrophages 
within  the  erythroblastic  islands, the  specialized 
niches  in  which  erythroid  precursors  proliferate, 
differentiate, and enucleate in the bone marrow 
5. 
These  hematopoietic  subcompartments  are 
composed  of  erythroblasts  surrounding  a  central 
macrophage. It was suggested that the macrophage 
functions  as  a  “nurse”  cell,  providing  iron  to 
developing  erythroblasts  for  heme  synthesis
6.  An 
attractive  hypothesis  proposed  for  central 
macrophages  is  that  ferritin,  synthesized  by 
macrophages,  secreted  via  exocytosis,  and 
subsequently taken up by erythroblasts could be a
source of iron for heme synthesis
7. It is not known 
whether  central  macrophages  might  release  iron 
also  by  the  ferroportin-dependent  exporting 
pathway and further studies are needed to clarify all 
this matter.  
The second pathway is the cycling of iron from 
hepatocytes to the blood and viceversa, according to 
body needs and the third is iron absorption through 
duodenal and upper jejunum that balances the 1-2 
mg  daily  iron  loss  occurring  through  cellular 
exfoliation  (see  below:  iron  absorption  and  iron 
storage paragraphs).  
Iron  transport  and  utilization: The  systemic 
transporter  of  iron in  the body  is  transferring, an 
abundant, high affinity iron-binding protein. Under 
normal circumstances, TF carries nearly all serum 
iron collected from duodenal absorptive epithelium, 
macrophages  and  hepatocytes,  and  dampens  its 
reactivity.  Very  small  amounts  of  iron  may  be 
loosely associated with albumin or small molecules. 
In  normal  human  subjects,  iron  occupies 
approximately  30%  of  the  iron-binding  sites  on 
plasma  TF
1.  The  saturation  of  TF  by  iron  shows 
diurnal fluctuation exhibiting a morning peak and 
an evening nadir
8. It is likely to be higher in the 
portal  circulation,  where  recently  absorbed  iron 
from the intestine enters the circulation and passes 
through the liver. This first-pass effect may explain 
the  periportal  iron  accumulation  in  the  hepatic 
lobule  observed  in  iron  overload  disorders 
associated with inappropriately increased intestinal Medit J Hemat Infect Dis 2009; 1; Open Journal System 
iron  absorption
9,10.  Conversely,  TF  saturation  is 
likely  lower  than  average  in  plasma  leaving  the 
erythroid  bone  marrow,  where  most  of  the  iron 
present is extracted for use by erythroid precursor 
cells.  The  erythroid  bone  marrow  is  the  largest 
consumer of iron. Normally, two-thirds of the body 
iron  endowment  is  found  in  developing erythroid 
precursors  and  mature  red  blood  cells.  Erythroid 
precursors express cell surface transferrin receptors 
(TfR1) that take up iron from holo-TF by receptor-
mediated endocytosis
11. Targeted disruption of the 
murine  TfR1  gene  causes  embryonic  lethality, 
attributable  to  severe  anemia
12.  Spontaneous 
mutations disrupting the TF gene demonstrate the 
importance of TF in animals 
13 and humans 
14. Lack 
of  TF  results  in  severe  iron  deficient  mycrocytic 
anemia.  However,  iron  deficiency  occurs  only  in 
hematopoietic  cells whereas  other  tissues  develop 
massive  iron  overload.  This  underscores  the 
importance  of  the  TF-TfR1  endocytic  cycle  in 
erythropoiesis
11, but further demonstrates that non-
hematopoietic cells have alternative mechanisms to 
assimilate iron. It also highlights changes in overall 
iron  homeostasis  that  result  from  iron  deficient 
erythropoiesis.  Hepcidin  synthesis  is  markedly 
depressed and intestinal iron absorption is increased 
in  congenital  hypo-transferrinemia,  apparently  to 
try to compensate for the lack of iron available to 
erythroid  precursors
13,15,16. This  is  compelling 
evidence for a signaling mechanism that allows the 
erythroid  bone  marrow  to  communicate  its  iron 
needs to the intestine’s absorptive epithelium (see 
below).
Iron absorption: Iron in food is present as ferric 
iron or as heme. Heme is a biologically important 
iron  containing  compound  and  a  key  source  of 
dietary  iron  but  the  mechanism  by  which  the 
enterocyte  takes  up  heme  and  catabolises  it  to 
utilise the iron is still poorly understood. Currently, 
there are two prevailing hypotheses explaining the 
mechanisms of this process; first, heme is taken up 
by  receptor  mediated  endocytosis;  secondly,  the 
recent  discovery  of  a  heme  transporter 
(PCFT/HCP1)  that  may  have  the  capability  of 
transferring heme from the small intestinal  lumen 
directly  into  the  cytoplasm
17.  One  important 
criticism  of  the  receptor  mediated endocytosis 
hypothesis  is  that  it  assumes  iron  released  from 
heme is transported out of the internalised vesicles 
in order to join the labile iron pool. Currently, no 
such  transport  process  has  been  identified. 
However,  it  is  possible  that  divalent  metal 
transporter  1  (DMT1)  may  fulfil  this  role  in  a 
manner  analogous  to  its  role  in  the  transferrin 
receptor  cycle.  In  recent  years,  two  mammalian 
heme  transporters  have  been  discovered,  namely 
PCFT/HCP1
18,19 and FLVCR
20possibly acting at the 
apical  and  basolateral  site  of  the  small  intestinal 
enterocyte,  respectively.  At  this  early  stage, 
however,  the  physiological  relevance  of  these 
transporters  to  intestinal  heme  iron  absorption  is 
unclear.  PCFT/HCP1  has  been  independently 
characterised  as  a  folate/proton  symporter  and 
appears  to  play  a  key  role  in  intestinal  folate 
absorption.  Interestingly,  the  folate  transport 
capabilities of PCFT/HCP1 are at least an order of 
magnitude  higher  than  that  observed  for  heme, 
suggesting  that  folate  may  be  the  more 
physiologically  relevant  target  of  this  transport 
protein.  FLVCR  is  a  heme  exporter  relevant  for 
erythropoietic  activity,  that  acts  as  an  overflow 
valve  for  excess  manufactured  heme  that  would 
otherwise result in cellular toxicity. Intestinal cell 
line CaCo-2 does express the protein and it might 
be  hypothesised  it  can  exert  similar  function  in 
intestinal cells too
21.
Much more knowledge has been developed on 
non-haem  iron  absorption
4,17. Non-haem  iron 
requires to be converted in ferrous iron by the apical 
ferric  reductase  duodenal  cytochrome  B although 
the physiological significance of this pathway is the 
subject  of  continued  debate.  Following  the 
reduction,  iron  crosses  into  the  cytoplasm  via  an 
apical iron transporter, DMT1
22. The physiological 
relevance of DMT1 in iron absorption, is confirmed 
in the Belgrade (b) rat and mk mouse which both 
exhibit a microcytic, hypochromic iron deficiency 
anaemia  due  to  a  G185R  mutation  to  DMT1, 
resulting  in  a  dramatic  decrease  in  DMT1 
function
23.
Cells  regulating  body  iron  homeostasis: Besides 
enterocytes  other  cell  lines,  namely macrophages, 
hepatocytes in adults and placental cells during fetal 
life,  have  core  functions  within  iron  metabolism, 
that  is  to  acquire  iron  from  different  sources 
(senescent erythrocytes and holotransferrin) and to 
deliver it to the rest of  the body according to its 
needs  (Figure  2).  To  do  this  important  function 
these  cells  have  a  specialised  mechanism  for 
exporting iron to plasma, that is the iron exporter 
ferroportin
24. Ferroportin needs copper-ferroxidases 
to  release  iron  to  plasma  transferrin,  namely 
hephaestin in duodenal cells
25 and ceruloplasmin in 
hepatocytes,  and  macrophages
4.  When  defective, 
these  proteins  induce  cellular  iron  retention  in 
specific cell types as shown in hephaestin deficient 
mice
26 and  in  humans  with  aceruloplasminemia
27. 
Ferroportin acts under the control of hepcidin and Medit J Hemat Infect Dis 2009; 1; Open Journal System 
Figure 2. Cells regulating body-iron homeostasis. Enterocytes, macrophages and hepatocytes acquire iron from different sources and 
deliver it to the rest of the body through the iron exporter ferroportin, which needs copper-ferroxidases to release iron to plasma 
transferrin. Ferroportin acts under the control of hepcidin and this interaction can explain the systemic regulation of iron metabolism.
this interaction can explain the systemic regulation 
of  iron  metabolism
28.  Interestingly,  it  has  been 
shown  that  hepcidin-induced  internalization  of 
ferroportin  requires  binding  and  cooperative 
interaction  with  Janus  kinase  (Jak2)
29.  Hepcidin 
binding to ferroportin results in the phosphorylation 
of  ferroportin,  a  step  necessary  for  its 
internalization by clathrin-coated pits and the kinase 
responsible  for  the  phosphorylation  is  Jak2.  This 
finding provides a mechanistic explanation for the 
dominant  inheritance  of  hepcidin  resistant 
ferroportin disease
30 and suggests that Jak2 might 
represent an important link at the interface between 
erythropoiesis and iron metabolism.
Iron  storage:  Following  phagocytosis  of  old  and 
damaged  erythrocytes,  tissue  macrophages, 
particularly in the spleen, lyse cells and catabolyse 
hemoglobin  presumably  by  heme  oxygenase,  to 
liberate  iron.  Some  iron  remains  stored  in 
macrophages, although some is exported to plasma 
TF.  Ferroportin  is  critical  for  macrophage  iron 
export  and  can  be  regulated  to  change  the  ratio 
between  stored  and  released  iron
24.  Hepatocytes 
represent the main depot for iron storage in normal 
conditions and in non-transfusional  iron  overload. 
Although  the  TF  cycle  may  be  involved  in 
hepatocyte  iron  acquisition  to  some  extent,  non–
transferrin-bound  iron  (NTBI)  uptake  pathways 
become  particularly  important  when  serum  iron 
levels exceed TF binding capacity
31,32. The identity 
of  the  hepatocyte  NTBI  uptake  system  is  not 
known,  but  DMT1  is  unlikely  to  be  involved, 
because  hepatocytes  can  accumulate  iron  in  the 
absence  of  DMT1
33.  Candidates  for  the  NTBI 
transporter  include  Zip14,  a  member  of  the 
SLC39A zinc transporter family, which can mediate 
the  uptake  of  zinc  and  NTBI  in  hepatocytes
34. 
Hepatocytes have a large capacity to store excess 
iron. Most storage iron is probably in the form of 
ferritin,  which  can  be  mobilized  when  needed 
elsewhere  in  the  body.  Eventually,  however, 
massive  iron  overload  results  in  hepatotoxicity; 
hepatitis leads to fibrosis and cirrhosis. The liver is 
probably  exposed  to  more  NTBI  than  are  other 
tissues because of the first-pass effect of the portal 
circulation.  However,  other  tissues  have  NTBI 
uptake  activities  and  load  iron  when  NTBI  is 
present  in  the  plasma.  The  heart  and  endocrine 
tissues are particularly susceptible; cardiomyopathy 
and  endocrinopathies  are  the  predominant 
nonhepatic complications of iron overload. L-type 
calcium channels
35 can mediate the uptake of NTBI 
in the myocardium, whereas other candidates, such 
as  transient  receptor  potential  canonical  protein 
TRPC6
36, need further confirm. 
Regulation  of  iron  homeostasis.  Hepcidin:  the 
master  regulator.  The  liver  peptide  hepcidin Medit J Hemat Infect Dis 2009; 1; Open Journal System 
regulates intestinal iron absorption and iron release 
from storage cells by binding ferroportin causing its 
internalization  and  degradation,  thus  exerting  a 
general  inhibitory  effect  on  iron  release  in  the 
body
28,37,38.  Animal  models  clarified  the  role  of 
hepcidin  as  hepcidin  knock-out  mice  developed 
massive  iron  overload
39 and  hepcidin  over-
expression  induced  iron  deficiency 
40.  In 
physiological  conditions,  hepcidin  production  is 
tightly  regulated  in  response  to  signals  released 
from other organs, prevalently from bone marrow 
(erythroid  regulator)  and  the  iron  stores  (store 
regulator). Hepcidin levels increase in iron overload 
in order to limit iron absorption and are reduced up 
to  undetectable  levels  in  iron  deficient 
erythropoiesis,  either dependent  from  decreased 
iron supply or increased erythroid iron requirement, 
to allow iron acquisition
16,37.
Studies on genetic disorders of iron metabolism 
and of corresponding animal models have identified 
the  hemochromatosis  proteins  (HFE,  TFR2  and 
HJV) as the iron-dependent regulators of hepcidin 
expression.  Patients  affected  by  hemochromatosis 
have a defective synthesis of hepcidin that is absent 
in JH, reduced in type 3 HH due to TFR2 mutation 
or  inadequate  to  the  amount  of  iron  overload  in 
classical HH
38. Such difference is related to the role 
of each protein in hepcidin regulation. HFE, TFR2 
and HJV  are  all  positive  regulators  and represent 
only a part of the complex regulation of hepcidin 
transcription,  as  summarised  in  Figure  3,  where 
mediators  and  signalling  pathways  of  iron-
inflammatory- and erythroid- dependent regulation 
of hepcidin are reported. Recent studies suggest a 
role  for  HFE  as  a  component  of  an  iron-sensing 
complex  that  involves  interactions  with  diferric 
transferrin,  TFR1  and  TfR2  at  the  plasma 
membrane  of  hepatocytes 
41,42.  Defective  HFE  or 
TFR2 prevents formation of a functional iron sensor 
and signal transduction effector complex leading to 
dysregulated  hepcidin  expression  as  observed  in 
hereditary  hemochromatosis.  Indeed,  double 
heterozygotes  for  HFE  and  TFR2  mutations 
develop hemochromatosis 
43, whereas this does not 
occur in carriers of single allelic mutations in both 
HFE  and  HJV
44,45,  suggesting  they  behave  to
different pathways of hepcidin regulation. The main 
activator of hepcidin in iron overload is HJV, the 
protein  mutated  in  type  2a  juvenile 
hemochromatosis: HJV-deficient patients and mice 
have undetectable levels of hepcidin
46,47. HJV is a 
GPI linked protein that activate hepcidin as a co-
receptor for Bone morphogenetic proteins (BMPs), 
a  family  of  cytokines  that  signal  through  SMAD 
proteins  as  a  second  messenger
48.  Several  BMPs 
may activate hepcidin in vitro but the relevant BMP 
in  vivo  is  BMP6,  since  knock  out  mice  for  this 
BMP  have  no  developmental  defect  but  develop 
severe iron overload
49. That the BMPs pathway is 
involved  in  iron  homeostasis  through  hepcidin 
regulation is further demonstrated by the severe iron 
overload and very low hepcidin expression reported 
in  Smad4  liver  conditional  knock  out
50.  Several 
other signals regulate hepcidin expression. Infection 
and  inflammation  markedly  increase  hepcidin 
synthesis  through  the  IL-6/IL-6  receptor  and 
STAT3 pathway, a mechanism largely implicated in 
the pathogenesis of anemia of chronic diseases
51,52. 
Hepcidin  inhibition  occurs  in  iron  deficiency, 
hypoxia  and  erythropoiesis  expansion  in  order  to 
increase iron export to plasma. Several inhibitors of 
hepcidin  have  been  proposed:  HIF-1a  that  is 
stabilised  in  hypoxia/iron  deficiency,  reduces 
hepcidin transcription by binding a HIF responsive 
element of hepcidin promoter
53, the soluble variant 
of  HJV  downregulates  hepcidin  in  vitro  by 
competing with mHJV for the BMP ligand
54, and 
matriptase 2 is a serin protease recently identified as 
a strong hepcidin inhibitor by cleaving membrane-
HJV
55. Accordingly, mutations in the gene coding 
matriptase 2 cause the rare form of iron refractory 
iron deficiency anemia in mice and humans
56. 
Erythroid-dependent  regulation  of  hepcidin: In 
vivo  studies  demonstrated  that  the  effect  is 
predominantly  due  to  the  activation  of 
erythropoiesis and to secondary changes in plasma 
and tissue iron
16. This was demonstrated by Pak et 
al
57 who  showed  that  erythropoietin  suppresses 
hepcidin synthesis, but that this effect was lost by 
pharmacologic  inhibition  of  erythropoiesis. 
Similarly,  Vokurka  et  al.
58 showed  a  dramatic 
increase  in  hepcidin  expression  in  mice  when 
erythropoiesis  was  inhibited  by  irradiation  or 
posttransfusion  polycythemia.  The  nature  of  the 
erythropoietic regulator of hepcidin is now debated, 
but may include one or more proteins secreted by 
developing erythrocytes. When HepG2  cells  were 
treated  with  sera  from  -thalassemia  patients,  in 
which  erythropoietic  drive  is  greatly  elevated,  or 
with  sera  from  HFE-hemochromatosis  or  control 
subjects,  only  -thalassemia  sera  decreased 
hepcidin  mRNA
59.  Another  study  treating  HepG2 
cells  with  sera  from  patients  with  iron-deficiency 
anemia  or  -thalassemia  showed  similar  results
60. 
Regulation of hepcidin by erythropoietic activity is 
of  particular  importance  in  iron-loading  anemias 
such  as  -thalassemias  and  diserytropoietic 
anemias. Studies in animal models of thalassemia Medit J Hemat Infect Dis 2009; 1; Open Journal System 
Figure 3. Signal pathways in systemic regulation of hepcidin. Many stimuli regulate expression of Hepcidin gene (HAMP) in the 
liver. One of the best known positive modulator is represented by Bone Morphogenetic Proteins (BMPs) that bind BMP-Receptor 
(BMP-R) on the surface of the hepatocyte resulting in SMAD-mediated induction of HAMP transcription. Hemojuvelin (mHJV) 
increases this signal acting as BMP co-receptor on the cell surface. In contrast, the soluble forms of HJV (sHJV), produced by HJV 
cleavage by furin at position 335, act as “decoy-receptor” competing with mHJV for the BMP ligand. Matriptase-2 (Mt2), which is 
activated by iron deficiency and by hypoxia, is the most potent inhibitor of hepcidin production by cleaving mHJV on hepatocyte 
surface and so preventing BMP-mediated hepcidin production. HAMP expression is also stimulated by inflammation, via the soluble 
mediator Interleukin-6 (IL6) and its specific membrane receptor (IL6-R) activating a STAT3-dependent signal pathway promoting 
HAMP  transcription.  HFE,  TfR2  and  TfR1  positively  influence  HAMP  transcription  in  a  ERK1/2  mediated  way  acting  as  a 
functional  molecular  complex  on  the  cell  surface  playing  a  primary  role  in  the  hepatocyte  sensing  of  circulating  iron  levels.  
Erythropoiesis,  via  the  soluble  mediator  Growth  Differentiation  Factor  15  (GDF15)  and  Twisted  Gastrulation  (TWSG)  1,  and 
hypoxia, via Hypoxia Inducible Factor (HIF), decrease HAMP expression (see text for further explanation). 
indicate  that  in  conditions  of  extreme  ineffective 
erythropoiesis,  there  is  relatively  little  peripheral 
destruction of red cells and iron accumulates more 
rapidly  in  the  liver  than  in  the  spleen,  consistent 
with  the  interpretation  that  iron  loading  results 
primarily  from  increased  intestinal  absorption
59,61. 
Thus,  very  high  erythropoietic  activity  and 
increased iron requirement from the bone marrow 
generates  a  signal  that  can  override  hepcidin 
regulation  by  iron,  leading  to  increased  iron 
absorption,  but  the  marrow  signal  that  modulates 
hepcidin  expression  is  debated  (Figure  4).  One 
proposed  hepcidin  inhibitor  in  these conditions  is 
GDF15,  a  cytokine  member  of  the  TGF-
superfamily  which  is  strongly  expressed  in 
hemoglobinized erythroblasts at the final stages of 
human erythropoiesis. GDF15 is hyperexpressed in 
thalassemia
62,  CDA  type  1
63 and,  although  at  a 
lower  level,  in  PKD    and  some  myelodisplastic 
syndromes and it might mediate the bone marrow 
signal to the liver by partially suppressing hepcidin 
synthesis, as shown in hepatocyte cell colture
16,62. 
Very recently, the same Authors, identified  twisted 
gastrulation  1  (TWSG1)  as  a  novel  erythroid 
regulator  of  hepcidin  expression  in  murine  and 
human  cells
64.  TWSG1  suppressed  hepcidin  in 
human  hepatocytes  through  a  BMP-dependent 
mechanism. It is proposed that TWSG1 and GDF15 
act  together  to  inappropriately  inhibit  hepcidin 
expression in thalassemia (Figure 4). Due to the Medit J Hemat Infect Dis 2009; 1; Open Journal System 
Figure 4. Hepcidin regulation by erythroid- iron- and hypoxia-related signals in iron-loading anemias. (GDF= growth differentiation 
factor; TWSG= twisted gastrulation; TF= holo-transferrin; HIF= hypoxia inducible factor)
expansion  of  erythropoiesis,  TWSG1  expressed 
during  the  early  stages  of  erythropoiesis  acts 
indirectly  by  inhibiting  BMP-mediated  expression 
of  hepcidin
64.  In  thalassemia,  over-expression  of 
TWSG1  would  inhibit  the  host’s  ability  to  sense 
and respond to iron loading. It is also hypothesised
that the increased expression of TWSG1 may also 
impact  erythropoiesis  in  thalassemia by  inhibiting 
the  BMP4  dependent  expansion  of  stress 
erythroblasts, which in  turn would  exacerbate the 
anemia.
The  role  of  hypoxi: Several  lines  of  evidence 
indicate  that iron  and  oxygen  homeostasis  are 
tightly connected. Anemia generates tissue hypoxia 
and  activates  the  cellular  mediator  of  biological 
response  to  hypoxia:  Hypoxia  inducible 
transcription factors: HIFs. This induce a signalling 
cascade  involving  hundreds  of genes.  Seminal 
studies established an association between oxygen 
and iron regulation by showing that hypoxia results 
in  higher  iron  absorption  in  mice  and  rats. 
Accordingly, both hypoxia and anemia induce the 
synthesis of erythropoietin (EPO) and are the two 
main  signals  that  increase  iron  absorption 
independently of iron stores
1,65. In addition, hypoxia 
was found to increase the expression of transferrin, 
transferrin  receptor,  ceruloplasmin  and 
hemoxygenase-1 which are hypoxia-inducible HIF-
1  target  genes,  thus  enabling  iron  transport  to 
erythroid tissue  and  cellular  uptake,  and  iron 
recycling and release from stores.
Hepcidin  is  suppressed  in  human  cultured 
hepatoma cells exposed to hypoxia
66 and HIF-1 has 
been  implicated  in  hypoxia-mediated  hepcidin 
regulation
53,66,67.  HIF-1  binds  to  the  hepcidin 
promoter  in  vitro  and  decreases  is  transactivation 
and  stabilization  of  HIF  in  hepatocytes  down-
regulates  hepcidin  and  increases  ferroportin 
expression in mice. Thus, HIF-1 acts as a regulator 
of iron homeostasis, but recent studies also suggest 
a  potential  role  of HIF-1 in  iron  sensing  in  the 
liver.  In  fact,  iron  deficiency  increases  HIF-1
levels in mice liver. In addition, one recent study 
demonstrates a role for HIF as a transcription factor 
that  regulates  the  expression  of  divalent  metal 
transporter  (DMT)-1  and  apical  ferric  reductase 
duodenal cytochrome b (Dcyt-b) genes, which are 
regulators of intestinal iron absorption
68. Thus, HIF 
may act both as an iron sensor and iron regulator, 
and be an essential link between iron and oxygen 
homeostasis  in  vivo  that  through  coordinate  gene 
regulation  mobilizes  iron  to  support  erythrocyte 
production.  Other  experimental  studies  further 
support  the  iron-oxygen  connection,  that  involves 
iron deficient and hypoxia-dependent production of 
soluble-HJV
69,  GDF15  and  Matriptase-2    in 
hepatocytes. Medit J Hemat Infect Dis 2009; 1; Open Journal System 
Iron  metabolism  in  thalassemia  and  sickle  cell 
disease: Patients affected by the most severe forms 
of thalassemia require chronic blood transfusions to 
sustain  life  and  chelation  therapy  to  prevent  iron 
overload.  Those  affected  by  -thalassemia 
intermedia  do  not  require  chronic  blood 
transfusions but eventually develop  elevated body 
iron  loads  due  to  ineffective  erythropoiesis  and 
hypoxia dependent hepcidin downregulation that, in 
turn,  induces  increased  gastrointestinal  iron 
absorption
16,61,70. Iron absorption studies in patients 
affected by beta thalassemia intermedia show that 
the  rate  of  iron  loading  from  the  gastrointestinal 
tract  is  approximately  three  to  four  times  greater 
than normal
71. In nontransfused patients with severe 
thalassemia,  abnormal  dietary  iron  absorption 
results in an increased body iron burden between 2 
and  5  g  per  year  depending  on  the  severity  of 
erythroid  expansion
72.  If  regular  transfusions  are 
required,  as  in  -thalassemia  major  patients,  this 
doubles the rate of iron accumulation. In addition to 
the transfusion-related iron overload, increased iron 
absorption also plays a role in -thalassemia major, 
in which its importance is inversely related to Hb 
levels
61,73.  As  loading  continues,  the  capacity  of 
transferrin,  the  main  transport  protein  of  iron,  to 
bind  and  detoxify  this  essential  metal  may  be 
exceeded.  The  resulting  nontransferrin-bound iron 
(NTBI)  fraction  within  plasma  may  promote  the 
generation  of  reactive  oxygen  species  (ROS), 
propagators  of  oxygen-related  damage
74.  Iron 
overload  is  responsible  for  the  most  damaging 
effects of the thalassemias, making iron chelation a 
focal point of the management of these diseases. In 
addition,  as  iron  accumulates  in  the  organs, 
dysfunction of the liver, endocrine glands, and heart 
become the main factors in limiting the survival of 
patients with -thalassemia
2. 
Iron  metabolism  in  SCD  largely  differs  as 
compared  to  thalassemia.  SCD  is  an  inherited 
disorder of hemoglobin synthesis characterized by 
life-long  hemolytic  anemia,  increased 
erythropoiesis  and  a  chronic  inflammatory  state 
with  endothelial  activation  and  enhanced  red  cell 
and leukocyte adhesion
75,76. There is no evidence of 
iron overload in non-transfused SCD patients, and 
iron  deficiency  may  be  even  develop, possibly 
related  to  intravascular  hemolysis  (which 
constitutes about a third of the hemolysis in SCD), 
and the resulting excessive urinary losses of iron
77. 
The  variable  clinical  spectrum  of  SCD  is  the 
consequence  of  multiple  events  and  genetic 
susceptibility that goes beyond the occurrence of a 
single  amino  acid  substitution  in  the  beta  globin 
chain of hemoglobin. SCD is as much a disease of 
endothelial dysfunction as it is a hemoglobinopathy 
that triggers erythrocyte polymerization. Hemolytic 
rate  is  associated  with  a  growing  list  of  clinical 
complications  of  SCD  that  fall  into  two  partially 
overlapping  subphenotypes:  a  viscosity–vaso-
occlusion  phenotype  versus  one  of  hemolysis-
endothelial  dysfunction.  The  viscosity-vaso-
occlusion subphenotype is associated with a lower 
hemolytic  rate,  marked  by  a  higher  hemoglobin 
level,  and  low  plasma  hemoglobin,  lactate 
dehydrogenase,  bilirubin  and  arginase  levels. 
Patients with these features have a higher incidence 
of vaso-occlusive pain crises, acute chest syndrome, 
and  osteonecrosis.  In  contrast,  patients  with  the 
hemolysis-endothelial  dysfunction  subphenotype 
exhibit  markers  of  high  hemolytic  rate,  including 
low  hemoglobin  level,  high  plasma  hemoglobin, 
LDH,  bilirubin,  and  arginase,  culminating  in  low 
nitric oxide bioavailability and high prevalence of 
pulmonary  hypertension,  leg  ulceration,  priapism, 
and stroke. Erythropoiesis is variably increased, but 
is not defective and nontransfused SCD patients do 
not spontaneously develop systemic iron overload, 
however,  microvascular  occlusion,  erythrocyte
sequestration  and  splenic  infarction  cause  splenic 
iron  overload
78.  In  contrast,  in  nontransfused 
thalassemic patients the spleen is enlarged but not 
iron-loaded because of the lack of transfusions and 
because low hepcidin levels favor iron mobilization 
from  reticuloendothelial  stores
78,79.  Chronic 
transfusion therapy partially normalize many of the 
disparities between the diseases.  In SCD patients, 
chronic  transfusion  therapy  lowers  the  percent 
sickle  hemoglobin  to  below  30%,  dramatically 
decreasing  intravascular  hemolysis,  splenic 
infarction, and the classic SCD vascular phenotypes 
associated  with  hemolysis  nitric  oxide 
dysregulation
75,80.  Patients  with  -thalassemia  and 
chronically  transfused  patients  with  SCD  develop 
severe iron overload with iron deposition in liver, 
heart,  spleen,  and  endocrine  organs
2,81.  Although 
having  similar  transfusional  burdens  and  somatic 
iron  stores,  patients  with  chronically  transfused 
SCD appear to be at lower risk for endocrinopathy, 
cardiac dysfunction, iron-mediated oxidative stress, 
and extrahepatic iron deposition
2. Risk for hepatic 
fibrosis during chronic transfusion therapy for SCD 
occurs  at  a  HIC  level  2.7-fold  higher  than 
historically  seen  in  thalassemia 
81.  Transferrin 
saturation and circulating nontransferrin bound iron 
levels  are  lower  in  transfused  patients  with  SCD 
relative  to  patients  with  TM  having  comparable 
somatic iron stores, suggesting disease-specific iron Medit J Hemat Infect Dis 2009; 1; Open Journal System 
handling
2,74. Some early reports link NTBI to iron-
related  cardiac  disease  and  may  explain  the 
prevalence of severe heart disease in thalassaemia 
with  their  higher  levels  of  NTBI  compared  to 
almost  no  cases  in  transfused  SCD
2.  It  has  been 
postulated  that  the  greater  systemic  inflammation 
observed in transfused patients with SCD may limit 
reticuloendothelial iron export and iron absorption 
through hepcidin or other iron mediators, but this 
hypothesis has never been proven
2,74. Recent data 
indicate  that,  despite  transfused  SCD  patients 
exhibiting heavy  total  body  iron  burden, they are 
monitored on a less frequent basis for iron-related 
organ  damage  compared  to  thalassemia  patients. 
The  reasons  for  these  discrepancies  are 
multifactorial and also likely include the perceived 
importance  of  the  procedure  by  either  the 
practitioner or the patient. Patients with SCD have 
far  more  acute  and  unpredictable  clinical  crises 
compared  to  patients  with  thalassemia;  therefore, 
iron risk assessment is not perceived as having high 
priority in clinical care management. What is clear 
from  these  preliminary  baseline  data  is  that  the 
disparity in the care of SCD patients who receive 
transfusions  requires  further  study  and  that 
guidelines for the assessment of this select group of 
patients should be supported by existing evidence 
and  expert  opinion,  until  the  full  effect  of  iron 
overload in this population is better understood. 
Hepcidin levels in thalassemia and SCD patients:
Thalassemia  intermedia  and  major  are  the  most 
studied human models  of hepcidin  modulation by 
ineffective  erythropoiesis  alone and the  combined 
and  opposite  effect  of  both  ineffective 
erythropoiesis  and  transfusion  dependent  iron 
overload, respectively. Regular transfusions, in fact, 
induce  massive  iron  loading  but  also  inhibit 
erythropoietic  drive.  Accordingly,  hepcidin 
production is higher in thalassemia  major than  in 
thalassemia intermedia although still inappropriate 
to  the  massive  transfusional  iron  loading  that 
partially  counteracts  the  erythropoietic-dependent 
hepcidin  downregulation
70,82,83.  Transfusions 
strongly influence hepcidin production as shown by 
the significant post-transfusion increase of urinary 
hepcidin  levels  in  thalassemia  patients,  probably 
related  to  transfusion  dependent  suppression  of 
erythropoiesis
84.  This  result  is  also  supported  by 
Jenkins et al
85 who found 5- to 8-fold increase in 
hepcidin  mRNA  in  liver  specimens  obtained  1–3 
days  after  red  cell  transfusion  in  patients  with 
thalassemia  major  and  SCD.  This  indicates  that 
hemoglobin  levels  at  the  time  of  biopsy  are  a 
significant  variable  in  determining  liver  hepcidin 
mRNA values. 
Data on hepcidin levels in SCD are very limited 
and no data are presently available on GDF15 and 
TWSG1  expression.  Kearney  et  al  found 
significantly  lower  levels  of  urinary  hepcidin  in 
nine  SCD  patients  when  compared  with  normal 
controls
84.  In  their  analysis,  hepcidin  levels  were 
negatively  correlated  with  markers  of  erythroid 
proliferation,  thus  supporting  the  theory  that 
hepcidin  production  is  suppressed  in  scenarios  of 
chronic  haemolytic  anemia  and  increased 
erythropoiesis.  This  finding,  however,  contrasts 
with  the  common  knowledge  that  non-transfused 
patients  with  SCD  do  not  develop  iron  overload.
Although  chronic  hemolysis  is  one  of  the  main 
features of SCD, the pathophysiology of SCD is not 
entirely red-cell related however, as vaso-occlusive 
crises and resultant tissue damage have been shown 
to  result  in  chronic  inflammation
74,76,  a  condition 
that  might  influence  hepcidin  production
51,86.  In 
addition, transfusional iron overload might further 
increase hepcidin production. Thus, hepcidin levels 
in patients with SCD might be under the influence 
of different and contrasting stimuli, possibly leading 
to marked variability. Very recently Kroot et al 
87
studied  hepcidin and  several  serum parameters  of 
erythropoietic, inflammatory and iron status in 16 
patients  with  SCD.  They  found  various  serum 
parameters to vary widely within this population. In 
particular,  they  observed  very  high  serum  ferritin 
levels not simply related to the transfusion history 
and in the presence of normal transferrin saturation. 
This  finding  confirms  that  serum  ferritin  in  SCD 
might  not  be  suitable  in  the  evaluation  of 
hepatocyte  iron  loading  and  suggest  an  iron 
distribution  pattern  of  the  anemia  of  chronic 
disease, with relatively more iron in the RE system. 
The  median  serum  and  urine  hepcidin-25  levels 
were  similar  for  patients  and  controls.  More 
precisely, serum hepcidin-25 levels were below the 
lower limit of detection in 5 SCD patients while in 
the  rest  they  were  within  the  normal  range. 
Interestingly  and  not  so  easy  to  explain,  the  five 
patients  with  the  lowest  hepcidin  levels  did  not 
show  marked  alterations  of  serum  iron  indices 
(transferrin  saturation  and  serum  ferritin  ranged 
between 23-72%,  and  40-213  g/L,  respectively). 
Results  confirmed  that  also  in  SCD  patients, 
erythropoiesis down-regulates hepcidin-25. In fact, 
when only sTfR was increased, serum hepcidin-25 
levels were in the lower normal range or even not 
detectable.  In  cases  where,  together  with  a 
substantially  increased  sTfR,  inflammation  and/or Medit J Hemat Infect Dis 2009; 1; Open Journal System 
high iron stores were also present, serum hepcidin-
25 levels were in the normal range confirming the 
induction of hepcidin by inflammation and elevated 
iron stores in SCD patients. 
Conclusion:  Erythropoiesis  and  iron  metabolism 
are inextricably linked. Hepcidin has a key role in 
coordinating    iron  procurement  according  to 
erythropoietic requirement. The recent tremendous 
advancement in the iron field have shed light on the 
various signals regulating hepcidin production and 
showed  that  erythroid-dependent  regulation  is 
absolutely  prevailing.  There  are  however,  some 
issues  to  be  clarified:  a.  if  mediators  other  than 
GDF15  and  TWSG1  exist  and  which  are  their 
interactions and mechanisms of hepcidin regulation; 
b. why, despite anemia and increased iron demand, 
and  the  evidence  of  reduced  hepcidin  synthesis, 
patients  with  haemolytic  anemias  do  not  develop 
the same amount of iron overload observed in the 
iron-loading  anemias  where  ineffective 
erythropoiesis  prevails  on  hemolysis.  New  links 
between  erythropoiesis  and  iron  metabolism  have 
recently  suggested:  the  link  between 
Epo/EpoR/Jak2/Stat5  signalling  and  TfR1  mRNA 
transcription 
88 and  the  role  of  Jak2  in  the 
phosphorylation and recycling of ferroportin 
29. In 
addition,  based  on  preliminary  studies  in  animal 
models of  thalassemia,  it has been suggested that 
use  of  Jak2  and  analogous  of  hepcidin  peptide 
might  have  a  role  in  limiting  ineffective 
erythropoiesis  and  increased  iron  absorption 
73. 
Greater  understanding  on  hepcidin  regulation  and 
function, and on the other molecules involved in the 
intricate  association  between  iron  and 
erythropoiesis, will shed light on new scenarios and 
will help develop more effective therapeutic options 
for  disorders  of  iron  homeostasis  and 
erythropoiesis. 
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